Back to Screener

Consumer Defensive

PURE Bioscience, Inc.(PURE)

Live Price

Offline

$0.07

+0.00% today

1Y Change

-36.36%

Window

Jun 23, 2025 β†’ Jun 15, 2026

Market Cap
$10.00M
Revenue Growth
+112075.2%
EPS Growth
+28.4%
Dividend Yield
0.0%

Coverage: 246 bars Β· Jun 23, 2025 β†’ Jun 15, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

PURE Bioscience, Inc. (PURE) is a Consumer Defensive stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.07 and down 36.4% across the available one-year price window (Jun 23, 2025 β†’ Jun 15, 2026). Baseline metrics include revenue growth of +112075.2%, EPS growth of +28.4%, a dividend yield of 0.0%. What stands out right now is revenue +112075.2%, EPS +28.4%, free cash flow -79512.8% with operating margin -82.3% and ROIC 1548.4%. Valuation is more restrained than many high-expectation growth names at price/sales 3.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PURE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Consumer Defensive peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+112075.2% vs +1.7% peer median

Operating Margin

Below sector median

-82.3% vs +6.6% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

The operating story is still moving forward

Revenue is running at +112075.2% and EPS at +28.4%, with operating margin around -82.3%.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

PURE

β€”

Normalized return

SPY

β€”

S&P 500

Excess Return

β€”

Relative to SPY

PURE Max Drawdown

-63.64%

Trailing 1Y

SPY Max Drawdown

β€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for PURE and SPY.

Calendar-year return history is still loading or unavailable.
PURE Bioscience, Inc. logo

Company Overview

PURE Bioscience, Inc.

Other OTC

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.

Leadership
Robert F. Bartlett
IPO Date
Aug 8, 1996
Employees
11
Street Address
9669 Hermosa Avenue
Mailing
El Cajon, CA, 91730
Region
El Cajon, CA, US
Reporting Currency
USD
Investor Line
619 596 8600
Last Updated
May 3, 2026
CIK: 0001006028ISIN: US74621T2096CUSIP: 74621T209
Reports in USDSEC Registered

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
β€”
EV/EBITDA
β€”
Price/Sales
3.3
Price/Book
β€”

Growth

Revenue
+112075.2%
EPS
+28.4%
Free Cash Flow
-79512.8%

Profitability

Gross Margin
54139.4%
Operating Margin
-82.3%
Net Margin
-89.8%
ROE
39.7%
ROIC
1548.4%

Balance Sheet

Debt/Equity
β€”
Current Ratio
0.25

Earnings Reports

No earnings data available

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.